In the Controversies in Cardiovascular Medicine article “Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox” by Strauss and Hall that appeared in the August 22, 2006, issue of the journal (Circulation. 2006;114:838–854), the first two sentences of the second paragraph under “ARB Congestive Heart Failure Trials: Poor Performance With Respect to MI” (page 844) contained two instances of the word “candesartan.” In both instances, “candesartan” should be replaced by “losartan,” to read as follows:
“In ELITE II (n=3152),78 losartan 50 mg was compared with captopril 50 mg 3 times daily, and total mortality was increased nonsignificantly by 13% in the losartan-treated group (280 versus 250 deaths) or, alternatively, was reduced by 13% in the captopril-treated group. Furthermore, losartan was associated with a 30% statistically nonsignificant increase in the secondary end point of sudden cardiac death or resuscitated arrest, an end point for which benefit had been expected on the basis of the findings of ELITE I.”
The authors regret these errors. These sentences have been corrected in the current online version of the article.